MULTIPLE SCLEROSIS, RELAPSING-REMITTING
Clinical trials for MULTIPLE SCLEROSIS, RELAPSING-REMITTING explained in plain language.
Never miss a new study
Get alerted when new MULTIPLE SCLEROSIS, RELAPSING-REMITTING trials appear
Sign up with your email to follow new studies for MULTIPLE SCLEROSIS, RELAPSING-REMITTING, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
MS drug trial for japanese patients halted early
Disease control TerminatedThis study tested a drug called natalizumab, given as a shot under the skin every 4 weeks, in Japanese adults with relapsing-remitting multiple sclerosis (MS). The goal was to see if it could reduce new brain lesions over 24 weeks. Only 21 people were enrolled, and the study was …
Matched conditions: MULTIPLE SCLEROSIS, RELAPSING-REMITTING
Phase: PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated May 17, 2026 00:29 UTC
-
MS drug trial halted early: RC18 shows promise but needs more study
Disease control TerminatedThis early-stage trial tested an experimental drug called RC18 in 8 people with relapsing-remitting multiple sclerosis (MS). The goal was to see if it is safe and can reduce the number of MS attacks. The study was stopped early, so results are limited. RC18 works by targeting the…
Matched conditions: MULTIPLE SCLEROSIS, RELAPSING-REMITTING
Phase: PHASE2 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC